The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Gayduk A.I.

Samara State Medical University, Samara, Russia

Vlasov Ia.V.

Kafedra nevrologii i neĭrokhirurgii Samarskogo gosudarstvennogo meditsinskogo universiteta

Spinal muscular atrophy in samara region. Epidemiology, classification, prospects for health care

Authors:

Gayduk A.I., Vlasov Ia.V.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(12): 88‑93

DOI: 10.17116/jnevro201911912188

Views: 6357

Downloaded: 173

Download PDF (RU)
Contact the author
Table of contents

To cite this article:

Gayduk AI, Vlasov IaV. Spinal muscular atrophy in samara region. Epidemiology, classification, prospects for health care. S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(12):88‑93. (In Russ.)
https://doi.org/10.17116/jnevro201911912188

 
МСФ на ЯМ
Close metadata

The paper addresses the problem of spinal muscular atrophy in Russia, in particular in Samara region. There are 58 alive patients, including 19 children, registered to June 2019 in the Samara Regional Clinical Hospital n.a. V.D. Seredavin. The authors discuss the classification and etiopathogenesis of spinal muscular atrophy, prospects for its pathogenetic therapy and prevention in Russia.

Keywords:

hereditary neuromuscular diseases
pathogenetic treatment
spinal muscular atrophy
genetic testing

Authors:

Gayduk A.I.

Samara State Medical University, Samara, Russia

Vlasov Ia.V.

Kafedra nevrologii i neĭrokhirurgii Samarskogo gosudarstvennogo meditsinskogo universiteta

List of references:

  1. Zabnenkova VV, Dadali EL, Polyakov AV. Proximal spinal muscular atrophy of types I—IV: peculiarities of molecular genetic diagnostics. Neurvno-Myshechnye Bolezni. 2013;3:27-31.
  2. Spiegler AWJ, Hausmanowa-Petrusewicz I, Borkowska J, Klopocka A. Population data on acute infantile and chronic childhood spinal muscular atrophy in Warsaw. Hum Genet. 1990;85:211-214.
  3. Zaldivar T, Montejo Y, Acevedo AM, Guerra R, Vargas J, Garofalo N, Alvarez R, Alvarez MA, Hardiman O. Evidence of reduced frequency of spinal muscular atrophy type I in the Cuban population. Neurology. 2005;65:636-638. https://doi.org/10.1212/01.wnl.0000172860.41953.12
  4. Mostacciuolo ML, Danieli GA, Trevisan C, Muller E, Angelini C. Epidemiology of spinal muscular atrophies in a sample of the Italian population. Neuroepidemiology. 1992;11:34-38. https://doi.org/10.1159/000110905
  5. Wilmshurst JM, Reynolds L, Van Toorn R, Leisegang F, Henderson HE. Spinal muscular atrophy in black South Africans: concordance with the universal SMN1 genotype. Clin Genet. 2002;62:165-168. https://doi.org/10.1034/j.1399-0004.2002.620210.x
  6. Lazarin GA, Haque IS, Nazareth S, Iori K, Patterson AS, Jacobson JL, Marshall JR, Seltzer WK, Patrizio P, Evans EA, Srinivasan BS. An empirical estimate of carrier frequencies for 400+ causal Mendelian variants: results from an ethnically diverse clinical sample of 23.453 individuals. Genet Med. 2013;15:178-186. https://doi.org/10.1038/gim.2012.114
  7. Sugarman EA, Nagan N, Zhu H, Akmaev VR, Zhou Z, Rohlfs EM, Flynn K, Hendrickson BC, Scholl T, Sirko-Osadsa DA, Allitto BA. Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical laboratory analysis of >72.400 specimens. European Journal of Human Genetics: EJHG. 2012;20:1:27-32. https://doi.org/10.1038/ejhg.2011.134
  8. Akhmedova PH, Zinchenko RA, Ugarov IV. Epidemiology of hereditary neuromuscular diseases in the Republic of Dagestan. Medicinskaya Genetika. 2014;2:19-24.
  9. Hendrickson BC, Donohoe C, Akmaev VR, Sugarman EA, Labrousse P, Boguslavskiy L, Flynn K, Rohlfs EM, Walker A, Allitto B, Sears C, Scholl T. Differences in SMN1 allele frequencies among ethnic groups within North America. (Letter). J Med Genet. 2009;46:641-644. https://doi.org/10.1136/jmg.2009.066969
  10. Jedrzejowska M, Milewski M, Zimowski J, Borkowska J, Kostera-Pruszczyk A, Sielska D, Jurek M, Hausmanowa-Petrusewicz I. Phenotype modifiers of spinal muscular atrophy: the number of SMN2 gene copies, deletion in the NAIP gene and probably gender influence the course of the disease. Acta Biochimica Polonica. 2009;56(1):103-108.
  11. Lefebvre S, Bürglen L, Reboullet S, Clermont O, Burlet P, Viollet L, Benichou B, Cruaud C, Millasseau P, Zeviani M. Identification and characterization of a spinal muscular atrophy-determining gene. Cell. 1995;80(1):155-165. https://doi.org/10.1016/0092-8674(95)90460-3
  12. Brzustowicz LM, Lehner T, Castilla LH, Penchaszadeh GK, Wilhelmsen KC, Daniels R, Davies KE, Leppert M, Ziter F, Wood D. Genetic mapping of chronic childhood-onset spinal muscular atrophy to chromosome 5q11.2-13.3. Nature. 1990;344(6266):540-541. https://doi.org/10.1038/344540a0
  13. Singh RN, Howell MD, Ottesen EW, Singh NN. Diverse role of survival motor neuron protein. Biochim Biophys Acta Gene Regul Mech. 2017;1860(3):299-315. Epub 2017 Jan 15. https://doi.org/10.1016/j.bbagrm.2016.12.008
  14. Singh NN, Shishimorova M, Cao LC, Gangwani L, Singh RN. A short antisense oligonucleotide masking a unique intronic motif prevents skipping of a critical exon in spinal muscular atrophy. RNA Biology. 2009;6(3):341-350. https://doi.org/10.4161/rna.6.3.8723
  15. Giavazzi A, Setola V, Simonati A, Battaglia G. Neuronal-specific roles of the survival motor neuron protein: evidence from survival motor neuron expression patterns in the developing human central nervous system. Journal of Neuropathology and Experimental Neurology. 2006;65(3):267-277. https://doi.org/10.1097/01.jnen.0000205144.54457.a3
  16. Iwahashi H, Eguchi Y, Yasuhara N, Hanafusa T, Matsuzawa Y, Tsujimoto Y. Synergistic anti-apoptotic activity between Bcl-2 and SMN implicated in spinal muscular atrophy. Nature. 1997;390(6658):413-417. https://doi.org/10.1038/37144
  17. Hebert MD, Shpargel KB, Ospina JK, Tucker KE, Matera AG. Coilin methylation regulates nuclear body formation. Developmental Cell. 2002;3(3):329-337. https://doi.org/10.1016/S1534-5807(02)00222-8
  18. Carnegie GK, Sleeman JE, Morrice N, Hastie CJ, Peggie MW, Philp A, Lamond AI, Cohen PT. Protein phosphatase 4 interacts with the Survival of Motor Neurons complex and enhances the temporal localisation of snRNPs. Journal of Cell Science. 2003;116(Pt 10):1905-1913. https://doi.org/10.1242/jcs.00409
  19. Meister G, Bühler D, Laggerbauer B, Zobawa M, Lottspeich F, Fischer U. Characterization of a nuclear 20S complex containing the survival of motor neurons (SMN) protein and a specific subset of spliceosomal Sm proteins. Human Molecular Genetics. 2000;9(13):1977-1986. https://doi.org/10.1093/hmg/9.13.1977
  20. Pellizzoni L, Charroux B, Rappsilber J, Mann M, Dreyfuss G. A functional interaction between the survival motor neuron complex and RNA polymerase II. The Journal of Cell Biology. 2001;152(1):75-85. https://doi.org/10.1083/jcb.152.1.75
  21. Pellizzoni L, Baccon J, Charroux B, Dreyfuss G. The survival of motor neurons (SMN) protein interacts with the snoRNP proteins fibrillarin and GAR1. Current Biology. 2001;11(14):1079-1088. https://doi.org/10.1016/S0960-9822(01)00316-5
  22. Williams BY, Hamilton SL, Sarkar HK. The survival motor neuron protein interacts with the transactivator FUSE binding protein from human fetal brain. FEBS Letters. 2000;470(2):207-210. https://doi.org/10.1016/S0014-5793(00)01320-X
  23. Gubitz AK, Mourelatos Z, Abel L, Rappsilber J, Mann M, Dreyfuss G. Gemin5, a novel WD repeat protein component of the SMN complex that binds Sm proteins. The Journal of Biological Chemistry. 2002;277(7):5631-5636. https://doi.org/10.1074/jbc.M109448200
  24. Baccon J, Pellizzoni L, Rappsilber J, Mann M, Dreyfuss G. Identification and characterization of Gemin7, a novel component of the survival of motor neuron complex. The Journal of Biological Chemistry. 2002;277(35):31957-31962. https://doi.org/10.1074/jbc.M203478200
  25. Mourelatos Z, Abel L, Yong J, Kataoka N, Dreyfuss G. SMN interacts with a novel family of hnRNP and spliceosomal proteins. The EMBO Journal. 2001;20(19):5443-5452. https://doi.org/10.1083/jcb.200304128
  26. Narayanan U, Ospina JK, Frey MR, Hebert MD, Matera AG. SMN, the spinal muscular atrophy protein, forms a pre-import snRNP complex with snurportin1 and importin beta. Human Molecular Genetics. 2002;11(15):1785-1795. https://doi.org/10.1091/mbc.E13-03-0118
  27. Young PJ, Day PM, Zhou J, Androphy EJ, Morris GE, Lorson CL. A direct interaction between the survival motor neuron protein and p53 and its relationship to spinal muscular atrophy. The Journal of Biological Chemistry. 2002;277(4):2852-2859. https://doi.org/10.1074/jbc.M108769200
  28. Oskoui M, Darras BT, DeVivo DC. Chapter 1. In: Sumner C.J., Paushkin S., Ko C.P. (eds.). Spinal Muscular Atrophy: Disease Mechanisms. Elsevier. 2017.
  29. Dadali EL, Nikitin SS, Konovalov FA, Akimova IA, Korostelev SA. Clinical and genetic characteristics of spinal muscular atrophy with predominant leg lesions caused by mutations in the DYNC1H1 gene. Neurvno-Myshechnye Bolezni. 2018;8(2):59-67. https://doi.org/10.1093/brain/awu169
  30. Lally C, Jones C, Farwell W, Reyna SP, Cook SF, Flanders WD. Indirect estimation of the prevalence of spinal muscular atrophy Type I, II, and III in the United States. Orphanet Journal of Rare Diseases. 2017;12:175. https://doi.org/10.1186/s13023-017-0724-z
  31. D’Amico A, Mercuri E, Tiziano FD, Bertini E. Spinal muscular atrophy. Orphanet Journal of Rare Diseases. 2011;6:71. https://doi.org/10.1186/1750-1172-6-71
  32. Wang CH, Finkel RS, Bertini ES, Schroth M, Simonds A, Wong B, Aloysius A, Morrison L, Main M, Crawford TO, Trela A Participants of the International Conference on SMA Standard of Care. Consensus statement for standard of care in spinal muscular atrophy. Journal of Child Neurology. 2007;22(8):1027-1049. https://doi.org/10.1177/0883073807305788
  33. Finkle RS, Serjesen T, Mercuri E; ENMC SMA Workshop Study Group. 218th ENMC International Workshop:Revisiting the consensus on standards of care in SMA Naarden, The Netherlands, 19-21 February 2016. Neuromuscular Disorders. 2017;27:596-605. https://doi.org/10.1016/j.nmd.2017.02.014
  34. Vlodavets DV, Kharlamov DA, Artemyeva SB, Belousova ED. Federal clinical recommendations (protocols) on diagnosis and treatment of spinal muscular atrophy in children. 2013. https://doi.org/10.21508/1027-4065-2017-62-6-23-28
  35. Recommendations for patient management and respiratory support in spinal muscular atrophy (SMA) types 1—3. First Conciliation Meeting of the Association «SMA Families» (Italy). Rome, Italy, 30—31 January 2015.
  36. Garber K. Big win possible for Ionis/Biogen antisense drug in muscular atrophy. Nature Biotechnology. 2016;34(10):1002-1003. https://doi.org/10.1038/nbt1016-1002
  37. Surosky RT, Urabe M, Godwin SG, McQuiston SA, Kurtzman GJ, Ozawa K, Natsoulis G. Adeno-associated virus Rep proteins target DNA sequences to a unique locus in the human genome. J Virol. 1997;71(10):7951-7959.
  38. Valeria P, Stefania C. Advances in spinal muscular atrophy therapeutics. Therapeutic Advances in Neurological Disorders. 2018;11. https://doi.org/10.1177/1756285618754501
  39. Malone DC, Dean R, Arjunji R, Jensen I, Cyr P, Miller B, Maru B, Sproule DM, Feltner DE, Dabbous O. Cost-effectiveness analysis of using onasemnogene abeparvocec (AVXS-101) in spinal muscular atrophy type 1 patients. Journal of Market Access & Health Policy. 2019;1. https://doi.org/10.1080/20016689.2019.1601484
  40. Pinard E, Green L, Reutlinger M, Weetall M, Naryshkin NA, Baird J, Chen KS, Paushkin SV, Metzger F, Ratni H. Discovery of a Novel Class of Survival Motor Neuron 2 Splicing Modifiers for the Treatment of Spinal Muscular Atrophy. Journal of Medicinal Chemistry. 2017;60:10:4444-4457. https://doi.org/10.1021/acs.jmedchem.7b00406
  41. Ratni H, Ebeling M, Baird J, Bendels S, Bylund J, Chen KS, Denk N, Feng Z, Green L, Guerard M, Jablonski P, Jacobsen B, Khwaja O, Kletzl H, Ko CP, Kustermann S, Marquet A, Metzger F, Mueller B, Naryshkin NA, Paushkin SV, Pinard E, Poirier A, Reutlinger M, Weetall M, Zeller A, Zhao X, Mueller L. Discovery of risdiplam, a selective survival motor neuron-2 (SMN2) gene splicing modifier for the treatment of spinal muscular atrophy (SMA). J Med Chem. 2018;61:6501-6517. https://doi.org/10.1021/acs.jmedchem.8b00741

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.